JNJ-26076713
JNJ-26076713 is a potent and orally active alpha V integrin antagonist with IC50 values of 2.3 nM and 6.3 nM for alpha (V) beta (3) and alpha (V) beta (5), respectively. JNJ-26076713 inhibits retinal neovascularization[1].
Product Specifications
CAS Number
669076-03-3
UNSPSC
12352005
Target
Integrin
Type
Reference compound
Related Pathways
Cytoskeleton
Applications
Metabolism-protein/nucleotide metabolism
Field of Research
Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/jnj-26076713.html
Solubility
10 mM in DMSO
Smiles
O=C(C[C@@H]([C@H]1CNC2=C(C1)C=CC=C2)CC3CCN(CC3)C(CCC4=CC=C5CCCN=C5N4)=O)O
Molecular Formula
C29H38N4O3
Molecular Weight
490.64
References & Citations
[1]Santulli RJ, et, al. Studies with an orally bioavailable alpha V integrin antagonist in animal models of ocular vasculopathy: retinal neovascularization in mice and retinal vascular permeability in diabetic rats. J Pharmacol Exp Ther. 2008 Mar;324 (3) :894-901.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
αvβ3; αvβ5
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC683298-100 1x 100 µL
TRAF1 (TNFR-Associated Factor 1) (Lymphomatoid Papulosis Marker) (TRAF1/3298), CF568 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
![2-Chloro-10,11-dihydro-11-oxo-dibenzo[b,f][1,4]oxazepine](https://cdn.genprice.uk/products/572/6860166516566/imageurl/trc-c365290-500mg.webp)
TRC-C365290-500MG 500 mg
2-Chloro-10,11-dihydro-11-oxo-dibenzo[b,f][1,4]oxazepine
Sign In for Pricing
View Details 
